MedTrace Logo

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

NCT03709758 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-16

No results posted yet for this study

Summary

This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML).

The drugs involved in this study are:

* Venetoclax
* Daunorubicin
* Cytarabine

Conditions

Interventions

DRUG

Venetoclax

Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die

DRUG

Daunorubicin

Chemotherapy is most effective at killing cells that are rapidly dividing.

DRUG

Cytarabine

Chemotherapy is most effective at killing cells that are rapidly dividing.

Sponsors & Collaborators

Principal Investigators

  • Richard Stone, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-17
Primary Completion
2025-02-23
Completion
2026-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03709758 on ClinicalTrials.gov